Locations:
Search IconSearch
June 18, 2019/Neurosciences

Identifying Risks Factors Associated With Extended Length of Stay in Posterior Segmental Instrumented Fusion for Adolescent Idiopathic Scoliosis

Effective pain relief and major postoperative complications correlate with length of stay, study finds

16-ort-2676-goodwin-hero-image-650x450pxl

The use of epidural analgesia (EA) may be a protective factor against extended length of stay (LLOS) in patients undergoing posterior segmental instrumented fusion (PSIF) for adolescent idiopathic scoliosis (AIS).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A retrospective cohort study, recently published in the journal Spine Deformity, analyzed a variety of demographic and surgical factors in order to identify independent risk factors associated with increased LOS. The two factors most strongly associated with LLOS were major postoperative complications and the use of EAs for pain management. Other factors with statistically significant correlations were female sex, ≥9 ±2 levels of fusion, amount of operative blood loss, major postoperative complications, lack of EA and higher thoracic kyphosis.

“Length of stay is important in an era of value-based care; however, studies such as this one are concerned with more than reimbursement,” states Ryan Goodwin, MD, Director of Cleveland Clinic’s Center for Pediatric and Adolescent Orthopaedics. “The modifiable risk factors we identified, such as effective pain relief and major postoperative complications, relate to patient safety and well-being and overall quality of care.”

Identifying risks factors associated with extended length of stay

The study involved retrospective analysis of data from pediatric scoliosis patients (n = 407) undergoing surgical correction from January 1, 2009 through December 31, 2017. Researchers defined a short length of stay (SLOS) as fewer than four days, and a LLOS as four or more days.

Of the patients included in this single-institution study, 232 had SLOS, with a mean stay of 3 ±0.5 days. The remaining 175 patients had LLOS, with a mean stay of 6 ±2 days. Researchers looked at factors related to a patient’s demographics, comorbidities and preoperative measurements of scoliosis curve, as well as factors related to the surgery itself and any complications.

Advertisement

Among the demographic characteristics, only female sex had statistically significant associations with LLOS. Higher thoracic kyphosis was the only preoperative radiographic measurement to correlate with LLOS. Comorbidities had no statistically significant impact on LOS.

In terms of surgery-related characteristics and postoperative complications, which might be considered somewhat modifiable risk factors, operative time and the number of osteotomies had no significant impact on LOS. Patients in whom 7 ±2 levels were fused had SLOS compared to patients who had 9 ±2 levels fused.

Opportunity to make meaningful improvements in quality of care

In patients with major postoperative complications, such as the development of motor weakness, the need for transfusion, infection or reoperation, the risk of LLOS increased 11-fold. Patients without EA for pain control, a modifiable factor, had a three-fold increased risk of LLOS. Comorbidities, preoperative curve Cobb angle and number of osteotomies did not have a statistically significant impact on LOS.

Dr. Goodwin notes, “To our knowledge, this is the largest single-institution study, looking at the most comprehensive list of potential risk factors that might impact length of stay in this patient population. One day in a U.S. hospital can cost up to $4,000. Lowering these costs by reducing the number of in-hospital recovery days is good for everyone involved—patients, providers and payers.”

Advertisement

Related Articles

Dr. Robert Fox against a decorative background with a podcast icon overlay
April 16, 2025/Neurosciences/Podcast
Emerging Therapeutic Options in Progressive Multiple Sclerosis (Podcast)

Long-awaited efficacy against disability progression appears to be at hand

medication vials, syringes, tablets and capsules on a tabletop
Early Intensive or Escalation Therapy for Relapsing-Remitting Multiple Sclerosis?

Extension of DELIVER-MS trial will clarify long-term clinical effects of dueling treatment philosophies

illustration of brain plus chemical diagram of tavapadon
April 11, 2025/Neurosciences/Research
TEMPO: Tavapadon Shows Promise as Both First and Adjunct Therapy in Parkinson’s

Dopamine agonist performs in patients with early stage and advanced disease

Illustration of head and brain to depict migraine pain
Transnasal Evaporative Cooling Effective for Acute Treatment of Migraine Pain

A flow of dehumidified room air delivered via at-home device modulates sphenopalatine ganglion

hand pointing at brain scans on a computer monitoring
Disability Progression Slowed for First Time in Nonrelapsing Secondary Progressive Multiple Sclerosis

BTK inhibitor tolebrutinib shows positive results in phase 3 HERCULES trial

brain MRI with arrow pointing to a cortical tuber
April 2, 2025/Neurosciences/Epilepsy
Subtyping of Tuberous Sclerosis Complex Promises More Personalized Treatment and Surveillance

Phenotypic clustering study reveals four distinct disease trajectories

Thomas Mroz, MD, against a decorative background
March 17, 2025/Neurosciences/Podcast
Surgical Treatment Landscape for Cervical Spondylotic Myelopathy (Podcast)

A host of factors shape when to intervene and which of three primary procedures to use

hand of a person doing a crossword puzzle
March 13, 2025/Neurosciences/Research
Novel Tool Assesses Dynamic Neurocognitive Adaptation Across a Lifetime

Validated scale provides a method for understanding how lifestyle may protect against Alzheimer's

Ad